NASDAQ:MNKD

MannKind Stock Forecast, Price & News

$4.42

-0.06 (-1.34 %)

(As of 07/23/2021 12:43 PM ET)

Add

Compare

Today's Range

$4.36

▼

$4.49

50-Day Range

$3.61

▼

$5.48

52-Week Range

$1.52

▼

$6.25

Volume46,935 shs

Average Volume3.54 million shs

Market Capitalization$1.10 billion

P/E RatioN/A

Dividend YieldN/A

Beta1.95

30 days | 90 days | 365 days | Advanced Chart

Receive MNKD News and Ratings via Email

Sign-up to receive the latest news and ratings for MannKind and its competitors with MarketBeat's FREE daily newsletter.

About MannKind

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. The company offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity used for the treatment of hypothyroidism. The company has a license and collaboration agreement with United Therapeutics Corporation for the development and commercialization of a dry powder formulation of Treprostinil (Tyvaso DPI) used for the treatment of pulmonary arterial hypertension; and Thirona Bio to evaluate the therapeutic potential of TGF-Ã inhibitor for the treatment of pulmonary fibrosis. MannKind Corporation was incorporated in 1991 and is headquartered in Westlake Village, California.

Mannkind Sponsored Study Titled 'Afrezza® INHALE-1 Study in Pediatrics (INHALE-1)' Published To ClinicalTrials.Gov, Study Not Yet Recruiting - Benzinga
July 23, 2021 | benzinga.com

First Week of MNKD September 17th Options Trading
July 19, 2021 | nasdaq.com

Should I Buy Houghton Mifflin Harcourt Co (HMHC)? - Yahoo Finance
July 15, 2021 | finance.yahoo.com

How Much Of MannKind Corporation (NASDAQ:MNKD) Do Institutions Own? - Yahoo Finance
July 9, 2021 | finance.yahoo.com

How Much Of MannKind Corporation (NASDAQ:MNKD) Do Institutions Own?
July 9, 2021 | finance.yahoo.com

Top Picks Mid-Year Updates- MannKind - Yahoo Finance
July 2, 2021 | finance.yahoo.com

Company News for Jun 29, 2021 - Yahoo Finance
June 29, 2021 | finance.yahoo.com

Company News for Jun 29, 2021
June 29, 2021 | finance.yahoo.com

MannKind (NASDAQ:MNKD) Shares Gap Down to $5.29
June 29, 2021 | americanbankingnews.com

MannKind welcomes recent CMS decision on inhaled insulin therapy - Seeking Alpha
June 28, 2021 | seekingalpha.com

See More Headlines

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:MNKD
Previous Symbol
CUSIP56400P20
CIK899460
Webwww.mannkindcorp.com
Phone818-661-5000
Employees240
Year Founded1991

Sales & Book Value

Annual Sales$65.14 million
Price / Sales16.91
Cash FlowN/A
Price / Cash FlowN/A
Book Value($0.78) per share
Price / Book-5.67

Profitability

EPS (Most Recent Fiscal Year)($0.20)
Net Income$-57,240,000.00
Net Margins-91.69%
Return on EquityN/A
Return on Assets-30.39%

Debt

Price-To-Earnings

Miscellaneous

Outstanding Shares249,160,000
Market Cap$1.10 billion
Next Earnings Date8/4/2021 (Estimated)
OptionableOptionable

Social Links

MarketRank^™

Overall MarketRank^™

1.41 out of 5 stars

Medical Sector

732nd out of 2,216 stocks

Pharmaceutical Preparations Industry

346th out of 866 stocks

3.4 Analyst's Opinion

Consensus Rating
MannKind has received a consensus rating of Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $6.30, MannKind has a forecasted upside of 43.2% from its current price of $4.40.
Amount of Analyst Coverage
MannKind has only been the subject of 1 research reports in the past 90 days.

2.2 Community Rank

Outperform Votes
MannKind has received 558 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
MannKind has received 737 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
MannKind has received 56.91% “underperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about MannKind and other stocks. Vote “Outperform” if you believe MNKD will outperform the S&P 500 over the long term. Vote “Underperform” if you believe MNKD will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
MannKind does not currently pay a dividend.
Dividend Growth
MannKind does not have a long track record of dividend growth.

0.8 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, MannKind insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 1.80% of the stock of MannKind is held by insiders.
Percentage Held by Institutions
42.93% of the stock of MannKind is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6 Earnings and Valuation

Earnings Growth
Earnings for MannKind are expected to grow in the coming year, from ($0.20) to ($0.15) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of MannKind is -16.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of MannKind is -16.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

MannKind (NASDAQ:MNKD) Frequently Asked Questions

Is MannKind a buy right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for MannKind in the last year. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" MannKind stock.
View analyst ratings for MannKind or view top-rated stocks.

What stocks does MarketBeat like better than MannKind?

Wall Street analysts have given MannKind a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but MannKind wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is MannKind's next earnings date?

MannKind is scheduled to release its next quarterly earnings announcement on Wednesday, August 4th 2021.
View our earnings forecast for MannKind.

How were MannKind's earnings last quarter?

MannKind Co. (NASDAQ:MNKD) announced its earnings results on Wednesday, May, 12th. The biopharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.04) by $0.01. The biopharmaceutical company had revenue of $17.44 million for the quarter, compared to analyst estimates of $16.08 million.
View MannKind's earnings history.

How has MannKind's stock price been impacted by Coronavirus (COVID-19)?

MannKind's stock was trading at $1.10 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, MNKD stock has increased by 300.0% and is now trading at $4.40.
View which stocks have been most impacted by COVID-19.

What price target have analysts set for MNKD?

5 Wall Street analysts have issued 12-month price objectives for MannKind's shares. Their forecasts range from $5.00 to $8.00. On average, they anticipate MannKind's stock price to reach $6.30 in the next twelve months. This suggests a possible upside of 43.2% from the stock's current price.
View analysts' price targets for MannKind or view top-rated stocks among Wall Street analysts.

Who are MannKind's key executives?

MannKind's management team includes the following people:

Dr. Michael E. Castagna, CEO & Director (Age 44, Pay $983k)
Mr. Steven B. Binder, Chief Financial Officer (Age 58, Pay $674.71k)
Mr. Joseph Kocinsky, Chief Technology Officer (Age 57, Pay $642.92k)
Dr. David B. Thomson, Exec. VP, Gen. Counsel & Sec. (Age 54, Pay $728.74k)
Dr. Stuart A. Tross, Chief People & Workplace Officer (Age 54, Pay $638.38k)
Ms. Rosabel Realica Alinaya, VP of Investor Relations & Treasury (Age 60)
Mr. John F. Bedard, Sr. VP of Worldwide Regulatory Affairs (Age 71)
Mr. James Patrick McCauley Jr., J.D., M.B.A., Chief Commercial Officer (Age 55)
Mr. Alejandro Galindo M.B.A., M.S., Chief Commercial Officer (Age 49)

Who are some of MannKind's key competitors?

Some companies that are related to MannKind include Amgen (AMGN), Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Alexion Pharmaceuticals (ALXN), Seagen (SGEN), Alnylam Pharmaceuticals (ALNY), Exact Sciences (EXAS), Incyte (INCY), Novavax (NVAX), BioMarin Pharmaceutical (BMRN), Repligen (RGEN), Neurocrine Biosciences (NBIX) and United Therapeutics (UTHR).
View all of MNKD's competitors.

What other stocks do shareholders of MannKind own?

Based on aggregate information from My MarketBeat watchlists, some companies that other MannKind investors own include Bausch Health Companies (BHC), Novavax (NVAX), Geron (GERN), ACADIA Pharmaceuticals (ACAD), Advanced Micro Devices (AMD), Chesapeake Energy (CHKAQ), Micron Technology (MU), NVIDIA (NVDA), Intel (INTC) and Gilead Sciences (GILD).

What is MannKind's stock symbol?

MannKind trades on the NASDAQ under the ticker symbol "MNKD."

How do I buy shares of MannKind?

Shares of MNKD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is MannKind's stock price today?

One share of MNKD stock can currently be purchased for approximately $4.40.

How much money does MannKind make?

MannKind has a market capitalization of $1.10 billion and generates $65.14 million in revenue each year. The biopharmaceutical company earns $-57,240,000.00 in net income (profit) each year or ($0.20) on an earnings per share basis.

How many employees does MannKind have?

MannKind employs 240 workers across the globe.

When was MannKind founded?

MannKind was founded in 1991.

What is MannKind's official website?

The official website for MannKind is www.mannkindcorp.com.

Where are MannKind's headquarters?

MannKind is headquartered at 30930 RUSSELL RANCH ROAD SUITE 300, WESTLAKE VILLAGE CA, 91362.

How can I contact MannKind?

MannKind's mailing address is 30930 RUSSELL RANCH ROAD SUITE 300, WESTLAKE VILLAGE CA, 91362. The biopharmaceutical company can be reached via phone at 818-661-5000 or via email at [email protected]

This page was last updated on 7/23/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here